These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 36877052)
1. Drug-Resistant Tuberculosis on the Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert MTB/XDR and Whole-Genome Sequencing Analysis. Truden S; Sodja E; Žolnir-Dovč M Microbiol Spectr; 2023 Mar; 11(2):e0276122. PubMed ID: 36877052 [TBL] [Abstract][Full Text] [Related]
2. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175 [TBL] [Abstract][Full Text] [Related]
3. Performance evaluation of the Xpert MTB/XDR test for the detection of drug resistance to Omar SV; Louw G; Ismail F; Liu X; Ngcamu D; Gwala T; van der Meulen M; Joseph L J Clin Microbiol; 2024 Aug; 62(8):e0022924. PubMed ID: 39058018 [TBL] [Abstract][Full Text] [Related]
4. Xpert MTB/XDR: a 10-Color Reflex Assay Suitable for Point-of-Care Settings To Detect Isoniazid, Fluoroquinolone, and Second-Line-Injectable-Drug Resistance Directly from Mycobacterium tuberculosis-Positive Sputum. Cao Y; Parmar H; Gaur RL; Lieu D; Raghunath S; Via N; Battaglia S; Cirillo DM; Denkinger C; Georghiou S; Kwiatkowski R; Persing D; Alland D; Chakravorty S J Clin Microbiol; 2021 Feb; 59(3):. PubMed ID: 33298611 [TBL] [Abstract][Full Text] [Related]
8. The diagnostic accuracy of the GenoType(®) MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs. Theron G; Peter J; Richardson M; Barnard M; Donegan S; Warren R; Steingart KR; Dheda K Cochrane Database Syst Rev; 2014 Oct; (10):CD010705. PubMed ID: 25353401 [TBL] [Abstract][Full Text] [Related]
9. Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa. Oostvogels S; Ley SD; Heupink TH; Dippenaar A; Streicher EM; De Vos E; Meehan CJ; Dheda K; Warren R; Van Rie A Microb Genom; 2022 Apr; 8(4):. PubMed ID: 35471145 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of Xpert MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first and second-line drugs in Uganda. Katamba A; Ssengooba W; Sserubiri J; Semugenze D; Kasule GW; Nyombi A; Byaruhanga R; Turyahabwe S; Joloba ML PLoS One; 2023; 18(8):e0284545. PubMed ID: 37590288 [TBL] [Abstract][Full Text] [Related]
11. Rapid Detection of Extensive Drug Resistance by Xpert MTB/XDR Optimizes Therapeutic Decision-Making in Rifampin-Resistant Tuberculosis Patients. Chen X; Li R; Ge S; Li Y; Cai C; Weng T; Zhang Y; Jiang J; Feng Z; Chen Y; Zhang Y; Ma J; Persing DH; Chen J; Tang YW; Sun F; Zhang W J Clin Microbiol; 2023 Jun; 61(6):e0183222. PubMed ID: 37249422 [TBL] [Abstract][Full Text] [Related]
12. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Heyckendorf J; Andres S; Köser CU; Olaru ID; Schön T; Sturegård E; Beckert P; Schleusener V; Kohl TA; Hillemann D; Moradigaravand D; Parkhill J; Peacock SJ; Niemann S; Lange C; Merker M Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133554 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of novel Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670 [TBL] [Abstract][Full Text] [Related]
14. Investigation of isoniazid and ethionamide cross-resistance by whole genome sequencing and association with poor treatment outcomes of multidrug-resistant tuberculosis patients in South Africa. Malinga L; Brand J; Jansen van Rensburg C; Cassell G; van der Walt M Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S36-S37. PubMed ID: 28043598 [TBL] [Abstract][Full Text] [Related]
15. TB drug susceptibility testing in high fluoroquinolone resistance settings. Saluzzo F; Masood F; Batignani V; Di Marco F; Majeed U; Ghazal A; Cirillo DM; Tahseen S IJTLD Open; 2024 May; 1(5):230-235. PubMed ID: 39022777 [TBL] [Abstract][Full Text] [Related]
16. Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Cao B; Mijiti X; Deng LL; Wang Q; Yu JJ; Anwaierjiang A; Qian C; Li M; Fang DA; Jiang Y; Zhao LL; Zhao X; Wan K; Liu H; Li G; Yuan X Infect Drug Resist; 2023; 16():3117-3135. PubMed ID: 37228658 [TBL] [Abstract][Full Text] [Related]
17. Increased expression of efflux pump genes in extensively drug-resistant isolates of Mycobacterium tuberculosis. Kanji A; Hasan R; Zhang Y; Shi W; Imtiaz K; Iqbal K; Shafiq S; Hasan Z Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S150. PubMed ID: 28043519 [TBL] [Abstract][Full Text] [Related]
18. Analysis of Discordance between Genotypic and Phenotypic Assays for Rifampicin-Resistant Bokop C; Faye LM; Apalata T Pathogens; 2023 Jul; 12(7):. PubMed ID: 37513756 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the MolecuTech Cho EJ; Kang MR; Kim JH; Lee JI; Son ES; Park CH; Aung WW; Lee JS Int J Tuberc Lung Dis; 2022 Sep; 26(9):869-874. PubMed ID: 35996285 [No Abstract] [Full Text] [Related]
20. Comparison of line probe assay to BACTEC MGIT 960 system for susceptibility testing of first and second-line anti-tuberculosis drugs in a referral laboratory in South Africa. Maningi NE; Malinga LA; Antiabong JF; Lekalakala RM; Mbelle NM BMC Infect Dis; 2017 Dec; 17(1):795. PubMed ID: 29282012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]